The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis
Open accessAbstract
BACKGROUND: In the elderly, traditional influenza inactivated vaccines are often only modestly immunogenic, owing to immunosenescence. Given that adjuvantation is a means of enhancing the immune response, the trivalent inactivated vaccine adjuvanted with MF59 (MF59-TIV) was specifically designed to overcome this problem. Considering that, for ethical reasons, the absolute effectiveness of an influenza vaccine in the elderly cannot be demonstrated in placebo-controlled studies, the present study aimed to assess the effectiveness of MF59-TIV in preventing influenza-related outcomes in the elderly. METHODS: We conducted a systematic review of observational studies aimed at evaluating the effectiveness of MF59-TIV against influenza-related outcomes. Results of single studies were pooled whenever possible. RESULTS: Of the 1993 papers screened, 11 (6 case-control, 3 cohort and 2 prospective case-control) studies were identified. Hospitalization due to pneumonia/influenza and laboratory-confirmed influenza were reported in more than one study, while other outcomes (influenza-like illness, cardio- and cerebrovascular accidents) were investigated only by one study each. Pooled analysis of four case-control studies showed an adjusted MF59-TIV effectiveness of 51% (95% CI: 39-61%) against hospitalizations for pneumonia/influenza among community-dwelling seniors. Pooled results of the adjusted vaccine effectiveness against laboratory-confirmed influenza were also high (60.1%), although the 95% CI passed through zero (-1.3 to 84.3%). Other single community-based studies showed very high effectiveness of MF59-TIV in preventing hospitalizations for acute coronary [87% (95% CI: 35-97%)] and cerebrovascular [93% (95% CI: 52-99%)] events. MF59-TIV proved highly effective [94% (95% CI: 47-100%] in reducing influenza-like illness among institutionalized elderly. Furthermore, MF59-TIV displayed greater efficacy than non-adjuvanted vaccines in preventing hospitalizations due to pneumonia/influenza [adjusted risk ratio 0.75 (95% CI: 0.57-0.98)] and laboratory-confirmed influenza [adjusted odds ratio 0.37 (0.14-0.96)]. CONCLUSIONS: Our results suggest that MF59-TIV is effective in reducing several influenza-related outcomes among the elderly, especially hospitalizations due to influenza-related complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In comparative vaccination trials of older individuals, MF59, widely used in Europe, outperformed the nonadjuvanted vaccine in inducing influenza virus-specific antibodies and improving clinical outcome”
From Successful and Maladaptive T Cell Aging (2017) · cites this paper as Domnich et al., 2017
In the citing paper
“emerging data following the recent development and deployment of new-generation, high-dose or adjuvanted influenza vaccines82 and an adjuvanted glycoprotein varicella zoster vaccine83 suggest that the provision of additional signals to the immune system by certain adjuvants (such as AS01 and MF59) can overcome immunosenescence.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
(2014) · Medical Entomology and Zoology · Cited by 17,633
Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments
Lo, C. K.-L., Mertz, D., & Loeb, M. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-45 · Cited by 2,477
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100
Vaccines against influenza WHO position paper – November 2012.
(2012) · PubMed · Cited by 782
Vaccines for preventing influenza in the elderly
Demicheli, V., Jefferson, T., Pietrantonj, C. D., Ferroni, E., Thorning, S., Thomas, R. E., & Rivetti, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004876.pub4 · Cited by 712
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review
Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., & Demicheli, V (2005) · The Lancet · doi:10.1016/s0140-6736(05)67339-4 · Cited by 601
Mortality benefits of influenza vaccination in elderly people: an ongoing controversy
Simonsen, L., Taylor, R. J., Viboud, C. G., Miller, M. A., & Jackson, L. A. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70236-0 · Cited by 520
Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers
Hartling, L., Milne, A., Hamm, M. P., Vandermeer, B., Ansari, M., Tsertsvadze, A., & Dryden, D. M. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.03.003 · Cited by 436
Vu, T., FARISH, S. J., Jenkins, M. A., & Kelly, H. A. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00041-5 · Cited by 375
The rationale for quadrivalent influenza vaccines
Ambrose, C. S., & Levin, M. J. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.17623 · Cited by 375
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Vaccines for preventing influenza in the elderly
Jefferson, T., Pietrantonj, C. D., Al‐Ansary, L. A., Ferroni, E., Thorning, S., & Thomas, R. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004876.pub3 · Cited by 283
Vaccine Epidemiology: Efficacy, Effectiveness, and the Translational Research Roadmap
Weinberg, G. A., & Szilagyi, P. G. (2010) · The Journal of Infectious Diseases · doi:10.1086/652404 · Cited by 230
Reed, C., Meltzer, M. I., Finelli, L., & Fiore, A. E. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.098 · Cited by 228
Pellegrini, M., Nicolay, U., LINDERT, K. A., Groth, N., & Cioppa, G. D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.08.101 · Cited by 183
Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., & Crovari, P. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00185-6 · Cited by 174
Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy
Mannino, S., Villa, M., Apolone, G., Weiss, N. S., Groth, N., Aquino, I. F. P., Boldori, L., Caramaschi, F., Gattinoni, A., Malchiodi, G., et al. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws313 · Cited by 171
Buynder, P. G. V., Konrad, S., Buynder, J. L. V., Brodkin, E., Krajden, M., Ramler, G., & Bigham, M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.059 · Cited by 159
Frey, S. E., Reyes, M. R. A.-D. L., Reynales, H., Bermal, N., Nicolay, U., Narasimhan, V., Forleo‐Neto, E., & Arora, A. K. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.013 · Cited by 143
Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
Tsai, T. F. (2013) · Infection & Chemotherapy · doi:10.3947/ic.2013.45.2.159 · Cited by 107
Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly
Manzoli, L., Ioannidis, J. P. A., Flacco, M. E., Vito, C. D., & Villari, P. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19917 · Cited by 103
Puig‐Barberà, J., Díez‐Domingo, J., Belenguer‐Varea, Á., Chavarri, G. S., Rodrigo, J. A. L., Pérez‐Hoyos, S., & Vidal, D. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.08.039 · Cited by 96
Self-citationMoa, A., Chughtai, A. A., Muscatello, D. J., Turner, R. M., & MacIntyre, C. R. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.06.064 · Cited by 84
Puig‐Barberà, J., Díez‐Domingo, J., Pérez‐Hoyos, S., Belenguer‐Varea, Á., & Vidal, D. G. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.017 · Cited by 79
Self-citationIob, A., Brianti, G., Zamparo, E., & Gallo, T. (2005) · Epidemiology and Infection · doi:10.1017/s0950268805003936 · Cited by 77
MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
Banzhoff, A., Pellegrini, M., Giudice, G. D., Fragapane, E., Groth, N., & Podda, A. (2008) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2008.00059.x · Cited by 70
Beck, C., McKenzie, B. C., Hashim, A. B., Harris, R. C., Zanuzdana, A., Agboado, G., Orton, E., Béchard‐Evans, L., Morgan, G. S., Stevenson, C. N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029249 · Cited by 62
Camilloni, B., Basileo, M., Valente, S., Nunzi, E., & Iorio, A. M. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011562 · Cited by 61
Gasparini, R., Amicizia, D., Lai, P. L., Rossi, S., & Panatto, D. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22231 · Cited by 53
Self-citationPuig‐Barberà, J., Díez‐Domingo, J., Arnedo-Pena, A., Ruiz‐García, M., Pérez-Vilar, S., Micó-Esparza, J. L., Belenguer‐Varea, Á., Carratalá‐Munuera, C., Gil-Guillén, V. F., & Chávarri, H. S. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.006 · Cited by 50
Self-citationEffectiveness of Influenza Vaccination in Institutionalized Older Adults: A Systematic Review
Chan, T.-C., Hung, I. F., Luk, J. K.-H., Chu, L., & Chan, F. H.-W. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.10.008 · Cited by 43
Cost–benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria
Gasparini, R., Lucioni, C., Lai, P. L., Maggioni, P., Sticchi, L., Durando, P., Morelli, P., Comino, I., Calderisi, S., & Crovari, P. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00507-8 · Cited by 40
Self-citationInfluenza Vaccines for the Future
Rappuoli, R., & Giudice, G. D. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0279-2 · Cited by 38
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)
Meningococcal, C. (2007) · Cited by 35
Rümke, H. C., Richardus, J. H., Rombo, L., Pauksens, K., Plaßmann, G., Durand, C., Devaster, J., Dewé, W., & Oostvogels, L. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-348 · Cited by 34
Spadea, A., Unim, B., Colamesta, V., Meneghini, A., D'Amici, A. M., Giudiceandrea, B., & Torre, G. L. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.077 · Cited by 24
Evaluating the case for trivalent or quadrivalent influenza vaccines
Baxter, D. N. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1091130 · Cited by 23
Puig‐Barberà, J., Natividad-Sancho, A., Calabuig-Pérez, J., Rodrigo, J. A. L., Pastor-Villalba, E., Martínez-Úbeda, S., Pérez-Vilar, S., & Díez‐Domingo, J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.070 · Cited by 22
Self-citationEmulsion-Based Adjuvants for Improved Influenza Vaccines
O’Hagan, D. T., Tsai, T. F., & Reed, S. G. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0279-2_14 · Cited by 21
Research works printed but not linked: 1
- Official Journal of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF>.
Cited by
Sorted by citations
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Immunosenescence and human vaccine immune responses
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0164-9 · Cited by 530
Vaccination in the elderly: The challenge of immune changes with aging
Ciabattini, A., Nardini, C., Santoro, F., Garagnani, P., Franceschi, C., & Medaglini, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.010 · Cited by 411
Successful and Maladaptive T Cell Aging
Goronzy, J. J., & Weyand, C. M. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.010 · Cited by 362
Aliberti, S., Cruz, C. S. D., Amati, F., Sotgiu, G., & Restrepo, M. I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00630-9 · Cited by 334
Metadata
- Authors
- Domnich, A., Arata, L., Amicizia, D., Puig-Barberà, J., Gasparini, R., & Panatto, D.
- Affiliations
- University of Genoa (IT)
- Corresponding author
- Panatto, Donatella
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 35
- Issue
- 4
- Pages
- 513-520
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2566538631
- Cited by
- 229
- References
- 42
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 15 · 2023: 16 · 2022: 28 · 2021: 39 · 2020: 29 · 2019: 33 · 2018: 31 · 2017: 12
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Vaccine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- MF59, adjuvanted influenza vaccine, trivalent inactivated influenza vaccine, older adults, vaccine effectiveness, immunosenescence, laboratory-confirmed influenza, acute coronary events, cerebrovascular events, influenza-like illness, institutionalized elderly, community-dwelling older adults, influenza prevention
- MeSH terms
- Adjuvants, Immunologic, Aged, Aged, 80 and over, Humans, Influenza, Human, Influenza Vaccines, Polysorbates, Squalene, Vaccines, Inactivated, Treatment Outcome, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
